Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Follicular 10Lymphoma 9Lymphoma, Mantle-Cell 8Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, B-Cell 4Lymphoma, Non-Hodgkin 3Waldenstrom Macroglobulinemia 2Recurrence 2Lymphoma, T-Cell, Peripheral 2Hodgkin Disease 2Proteostasis Deficiencies 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Immunoglobulin Light-chain Amyloidosis 1Immunoblastic Lymphadenopathy 1Hematopoietic and Lymphoid System Neoplasm 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Central Nervous System Neoplasms 1Advanced Solid Tumor 1

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Proteostasis Deficiencies × Bendamustine Hydrochloride × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡